Colon Cancer Clinical Trial
Official title:
Natural Compounds to Reduce Nitrite in Meat Products: PHYTOME
The PHYTOME project (Phytochemicals to reduce nitrite in meat products) is a major European
Union (EU) co-funded research project that aims to develop innovative meat products in which
the food additive nitrite has been replaced by natural compounds originating from fruits and
vegetables. These biologically active compounds, also referred to as phytochemicals, are
known to contribute to improved gut health and are added to the meat as natural extracts.
In a number of meat products, carefully selected combinations of natural antioxidants and
other biologically active compounds occurring in vegetables, fruits and natural extracts such
as coffee and tea, will be added during meat processing. Some of these compounds possess an
antimicrobial activity allowing them to replace nitrite, whereas others possess a natural red
colour that may contribute to the desired appearance of the products. Also, some of these
compounds are known to protect colonic cells against damaging effects of cancer causing
agents that may be formed in the large intestine after meat consumption.
The PHYTOME project will develop new technologies to introduce the natural extracts during
processing to different types of meat products. These techniques will guarantee good sensory
quality of the product as well as microbiological safety. Once these techniques have been
developed and optimized at laboratory scale, the new type of products will be produced on an
industrial scale. The health promoting effects of these products will be evaluated in a human
dietary intervention study with healthy volunteers. After consumption of a fully controlled
diet with either relatively high amounts of the traditional meat products or products
produced following the new concept, faeces and colonic material will be collected and
investigated for markers of colorectal cancer risk. These investigations will be performed in
close collaboration with Research Institutes in the United Kingdom, Belgium, Italy and
Greece, and will make use of the newest genomics techniques that are available.
Rationale:
The aim of this project is to develop new meat processing technologies, resulting in
innovative meat products that have low or no nitrite and that have been shown to contribute
to improved human health. This will be achieved by introducing carefully selected mixtures of
biologically compounds originating from natural plant extracts. The new meat products will be
evaluated in a human dietary intervention study to establish their positive effect on cancer
risk markers in colonic tissues using the newest genomics techniques available.
Objective:
This project aims to evaluate the health impact of newly developed low nitrite containing
meat products using genomics markers in a human dietary intervention study.
Study design:
This study has a cross-over design with only healthy volunteers. Each participant will be
asked to donate a urinal, faecal and blood sample and undergo endoscopy after each
intervention period. All analyses will be done for each study group separately to examine the
overall effects of nitrite levels in meat.
Study population:
All subjects will be recruited by the University of Maastricht (UM) in the province of
Limburg, the Netherlands, using advertisements in local newspapers as well as other media.
Healthy subjects of both sexes will be selected based on predefined inclusion criteria (BMI:
18-25; > 18 years) and randomly assigned to one of the different experimental groups.
Intervention (if applicable):
Subjects will receive a completely controlled diet with 3 different types of meat products
according to the study design, with either normal levels, low or no added nitrite. After each
of the three intervention periods of 15 days (300 grams meat per day) blood, urine, saliva,
mouth wash and faeces will be sampled and stored appropriately at UM for later analysis.
Additionally, colonic biopsies will be taken by the department of internal medicine (UM) or
at the hospital of Sittard during an endoscopic examination. To evaluate the impact of
nitrate in drinking water on the endogenous nitrosation processes in combination with
processed red meat intake, there will be and extra intervention period of 7 days were
volunteers will be asked to consume drinking water with high nitrate levels according to the
Acceptable Daily Intake level (ADI: 3.7mg/kg bodyweight) in combination with 300 grams
processed red meat per day. Also after this intervention period volunteers will be asked to
collect a blood and saliva sample and 24h urine and faeces samples. Also, colonic biopsies
will be taken by the department of internal medicine (UM) or at the hospital of Sittard
during an endoscopic examination.
Main study parameters/endpoints:
- Formation of N-nitrosocompounds in human faecal and urine samples
- Reveal differences in transcriptomic and epigenomic markers after consumption of meat
products enriched with natural compounds. These markers can be interpreted as an
indicator of reduced cancer risk.
- Correlating gene expression changes to changes in genotoxic endpoints (DNA damage,
reduction in N-Nitroso compounds (NOC)) to reveal the molecular processes involved in
cancer risk reduction. The identification of molecular pathways that are crucial in the
carcinogenic process will demonstrate a causal association between dietary changes and
markers of carcinogenic risk.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT03457454 -
Reducing Rural Colon Cancer Disparities
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03390907 -
Hybrid APC Assisted EMR for Large Colon Polyps
|
N/A | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT04079478 -
The AID Study: Artificial Intelligence for Colorectal Adenoma Detection
|
||
Active, not recruiting |
NCT04057274 -
Acute Effect of modeRate-intensity aerOBIc Exercise on Colon Cancer Cell Growth
|
N/A | |
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05147545 -
Impact of Exercise and Hyperlipidic Meal on Free Circulating DNA in Patients With Metastatic Colonic Cancer and Healthy Subjects
|
N/A | |
Recruiting |
NCT05026268 -
The Laparoscopic Right Colectomy With Intracoroporeal Anastomosis
|
N/A | |
Not yet recruiting |
NCT03277235 -
Effect of a Resilience Model-Based Care Plan in Newly Diagnosed Colorectal Cancer Patients
|
N/A | |
Active, not recruiting |
NCT02959541 -
PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer
|
N/A | |
Active, not recruiting |
NCT02730702 -
Colon Cancer Risk-stratification Via Optical Analysis of Rectal Ultrastructure
|
||
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Recruiting |
NCT02577627 -
Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC
|
N/A | |
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
Recruiting |
NCT02526836 -
Complete Mesocolic Excision With Central Vessel Ligation Compared With Conventional Surgery for Colon Cancer
|
Phase 2/Phase 3 |